Tricida, Inc.
7000 Shoreline Court, Suite 201
South San Francisco
California
94080
United States
111 articles about Tricida, Inc.
-
Tricida plans to request a Type A meeting with the FDA, which is expected to take place in the fourth quarter of this year. This meeting will decide the future of veverimer.
-
Tricida Receives Complete Response Letter from the FDA for its New Drug Application for Veverimer for the Treatment of Metabolic Acidosis and Slowing of Kidney Disease Progression in Patients with Metabolic Acidosis Associated with CKD
8/24/2020
Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Appli
-
With a busy August on the U.S. Food and Drug Administration’s schedule, this week is no exception. Here’s a look at some of what’s on the agency’s calendar.
-
Tricida Announces Second Quarter 2020 Financial Results
8/5/2020
Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today financial results for the three and six months ended June 30, 2020 and provided an update on key initiatives.
-
Tricida to Report Second Quarter 2020 Financial Results and Host Conference Call and Webcast on Wednesday, August 5, 2020
7/29/2020
Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its second quarter 2020 financial results after the close of market on Wednesday, August 5, 2020. Tricida will host a conference call and webcast at 4:30 pm Eastern Time to discuss its financial results and business progress.
-
Tricida Provides Regulatory Update on Veverimer
7/15/2020
Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that on July 14, 2020
-
Tricida Announces that 2020 Annual Meeting Will be Held in Virtual Format - June 03, 2020
6/3/2020
Tricida, Inc. announced that, due to public health concerns relating to the coronavirus pandemic and to protect the health of its employees, directors and stockholders, its 2020 annual meeting of stockholders will be held in a virtual-only format.
-
Tricida to Present at the Goldman Sachs Virtual Healthcare Conference
6/2/2020
Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the Goldman Sachs 41 st Annual Global Healthcare Conference on Tuesday, June 9, 2020 at 1:40 pm PT / 4:40 pm ET. Tricida will provide a company overview, business update and progress on the company’s key initiatives. A live webcast of the presentation will be accessible on the Tricida website at IR.Tricida.com . An archive of the webca
-
Tricida Announces Closing of Offering of $200 Million of 3.50% Convertible Senior Notes Due 2027, Including Full Exercise of Option to Purchase Additional Notes
5/22/2020
Tricida, Inc. (Nasdaq: TCDA) , a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), today announced the closing of its previously announced offering of $200.0 million aggregate principal amount of its 3.50% Convertible Se
-
Tricida Prices Offering of $175 Million 3.50% Convertible Senior Notes Due 2027
5/20/2020
Tricida, Inc. announced the pricing of its offering of $175.0 million aggregate principal amount of its 3.50% Convertible Senior Notes due 2027 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
-
Tricida Announces Proposed Offering of $175 Million Convertible Senior Notes Due 2027
5/19/2020
Tricida, Inc. (Nasdaq: TCDA) today announced that it intends to offer $175.0 million aggregate principal amount of its Convertible Senior Notes due 2027 (the “Notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In connection with the offering, Tricida expects to grant the initial purchasers a
-
Tricida Announces First Quarter 2020 Financial Results
5/7/2020
Tricida, Inc., a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease, announced financial results for the three months ended March 31, 2020 and provided an update on key initiatives.
-
Tricida to Report First Quarter 2020 Financial Results and Host Conference Call and Webcast on Thursday, May 7, 2020
4/30/2020
Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its first quarter 2020 financial results after the close of market on Thursday, May 7, 2020
-
Tricida to Present at the Needham Virtual Healthcare Conference
4/9/2020
Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 19th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2020 at 6:20 am PT / 9:20 am ET.
-
Tricida Announces Multiple Data Presentations on Veverimer and Metabolic Acidosis to Be Given at the Virtual National Kidney Foundation 2020 Spring Clinical Meetings
3/24/2020
Tricida Announces Multiple Data Presentations on Veverimer and Metabolic Acidosis to Be Given at the Virtual National Kidney Foundation 2020 Spring Clinical Meetings SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients wi
-
Tricida Supports the National Kidney Foundation in Asking “Are You the 33%?”
3/12/2020
Tricida, Inc. announced that it is an executive sponsor of the National Kidney Foundation’s newest public awareness campaign which focuses on the 33 percent of American adults at risk for developing dangerous, life-threatening kidney disease.
-
Tricida Hires Robert McKague as Executive Vice President, General Counsel & Chief Compliance Officer
3/9/2020
Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), today announced the hiring of Robert McKague as Executive Vice President, General Counsel and Chief Compliance Officer.
-
Tricida Announces Fourth Quarter and Full-Year 2019 Financial Results
2/27/2020
Tricida, Inc. (Nasdaq: TCDA) announced today financial results for the fourth quarter and full-year ended December 31, 2019.
-
Tricida to Present at the Cowen 40th Annual Health Care Conference
2/24/2020
Feb. 24, 2020 21:15 UTC Tricida to Present at the Cowen 40 th Annual Health Care Conference SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the Cowen 40 th Annual Health Care Conference on Monday, March 2, 2020 at 11:10 am PT / 2:10 pm ET. Geoff Parker, Tricida’s Chief Financial Officer, will provide a company overview, business update and progress on the company’s key initiatives. A live webcast of the pr
-
Tricida to Report Fourth Quarter and Year End 2019 Financial Results and Host Conference Call and Webcast on Thursday, February 27, 2020
2/19/2020
Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), today announced that it will report its fourth quarter and year ended December 31, 2019 financial results after the close of market on Thursday, February 27, 2020.